Cancer Cause and Prevention Research in Maryland
Cancer Cause and Prevention Research (93.393) awarded $47.6 million to recipients in Maryland in 51 grants from fiscal 2021 to 2025, 1.3% of the program's national total. The Johns Hopkins University received the most, $22.2 million.
- Awarded in Maryland$47.6 million
- Awards51
- Share of the program1.3%
- Rank among states23rd of 48
- National total$3.6 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 23 | $8.8 million |
| FY 2022 | 28 | $10.2 million |
| FY 2023 | 21 | $6.5 million |
| FY 2024 | 25 | $9.3 million |
| FY 2025 | 23 | $12.6 million |
Recipients in Maryland
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Colleges and universities | 22 | $22.2 million |
| University of Maryland, Baltimore | Colleges and universities | 10 | $13.9 million |
| University of Maryland, College Park | Other | 4 | $7.9 million |
| Radiopharmaceutical Imaging and Dosimetry, LLC | Small businesses | 2 | $2.4 million |
| Medstar Health Research Institute Inc. | Nonprofits | 2 | $695,867 |
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Nonprofits | 1 | $424,525 |
| Federation of American Societies for Experimental Biology | Nonprofits | 8 | $62,347 |
| American Urological Association Education and Research, Inc | Nonprofits | 1 | $3,897 |
| Pacific Institute for Research & Evaluation | Nonprofits | 1 | $922 |
Open opportunities under this program
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
- Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
See all 60 on the program page
Questions people ask
How much Cancer Cause and Prevention Research money goes to Maryland?
$47.6 million from fiscal 2021 to 2025, across 51 awards. Maryland ranks 23rd of 48 states and territories for this program.
Who receives Cancer Cause and Prevention Research money in Maryland?
The largest recipient is The Johns Hopkins University, with $22.2 million in 22 awards. Next are University of Maryland, Baltimore and University of Maryland, College Park.
Can organizations in Maryland apply now?
Yes, 60 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cancer Cause and Prevention Research in other states
Other large programs in Maryland
- Grants to States for Medicaid
- Greenhouse Gas Reduction Fund: National Clean Investment Fund
- Education Stabilization Fund
- Highway Planning and Construction
- USAID Foreign Assistance for Programs Overseas
- 1332 State Innovation Waivers
- Disaster Grants - Public Assistance (Presidentially Declared Disasters)
- National School Lunch Program
- Children's Health Insurance Program
- Title I Grants to Local Educational Agencies